Meeting
2016 Genitourinary Cancers Symposium
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Authors
Mallika Sachdev Dhawan
University of California, San Francisco, San Francisco, CA
Mallika Sachdev Dhawan , Mina Lee , Alan H. Bryce , Vivian K. Weinberg , Charles J. Ryan , Christina Louise Derleth , Andrea Lynne Harzstark , Eric Jay Small , Rahul Raj Aggarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01594918
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 202)
DOI
10.1200/jco.2016.34.2_suppl.202
Abstract #
202
Poster Bd #
H17
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Rahul Raj Aggarwal
Poster
2014 Genitourinary Cancers Symposium
A multicenter phase I study of cabazitaxel (Cbz), mitoxantrone (Mito), and prednisone (Pred) (CAMP) for chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Rahul Raj Aggarwal
Poster
2015 Genitourinary Cancers Symposium
Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)
First Author: Ethan M. Basch
Poster
2015 Genitourinary Cancers Symposium
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.
First Author: Ovidio Fernandez Calvo